###### Key messages

What is already known about this subject?
=========================================

-   Low-dose glucocorticoids are an important treatment option in rheumatoid arthritis (RA), with proven clinical, functional and structural benefits.

-   Both the European League Against Rheumatism and the Canadian Rheumatology Association advise tapering glucocorticoid dose as rapidly as clinically feasible to minimise long-term safety concerns.

What does this study add?
=========================

-   This paper reports concomitant glucocorticoid use in patients with established RA who participated in the ACTION ([A]{.ul}bata[C]{.ul}ep[T]{.ul} [I]{.ul}n r[O]{.ul}uti[N]{.ul}e clinical practice) study and received at least one biologic agent prior to abatacept initiation.

-   For patients who remained on intravenous (IV) abatacept at 24 months, 40.7% were able to decrease their dose of glucocorticoids, including 26.9% who decreased their dose from \>5 mg/day to ≤5 mg/day.

How might this impact on clinical practice?
===========================================

-   This is the first study to describe concomitant glucocorticoid treatment patterns with abatacept in a real-world clinical setting and demonstrates that reduction and/or cessation of glucocorticoid therapy is possible with IV abatacept in clinical practice.

In patients with rheumatoid arthritis (RA) and poor prognosis, current treatment recommendations from the European League Against Rheumatism (EULAR) suggest initiating a biological agent in combination with methotrexate, with or without glucocorticoids, after failure of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).[@R1] Low-dose glucocorticoids (≤5 mg/day prednisone or equivalent)[@R1] remain an important treatment option given their capacity to increase clinical, functional and structural efficacy when combined with csDMARDs.[@R1] However, EULAR[@R1] and the Canadian Rheumatology Association[@R2] advise tapering the glucocorticoid dose as rapidly as clinically feasible to minimise safety concerns associated with prolonged use.[@R1]

ACTION (AbataCepT In rOutiNe clinical practice) is a non-interventional, international, multicentre cohort study to assess the long-term retention and effectiveness of intravenous abatacept in patients with RA in clinical practice in Europe and Canada (used in accordance with local licensing).[@R4] [@R5] The study design, ethics approvals, baseline demographics, disease and clinical characteristics, and primary outcomes have been reported elsewhere.[@R6]

Patients with established, moderate-to-severe RA, who were naïve to biological therapy or had received ≥1 previous biological agent, were enrolled prospectively (Cohort A; May 2008--December 2010) and followed for up to 24 months or up to 6 months after abatacept discontinuation.[@R6] We report patterns of concomitant glucocorticoid use over 24 months in biological-experienced patients (primarily from Europe); the majority of patients in cohort A experienced failure of at least one prior biological agent (89.2%) and it is the data from this subset that are reported here. Patients were included if they remained on abatacept at 24 months and had a clinical visit within the predefined 24-month time point, with glucocorticoid dose data available at initiation and 24 months. Glucocorticoid dose was assessed using the median of the area under the curve (mg/day) and glucocorticoid use was stratified by dose.

From May 2008 to December 2010, 1137 patients were enrolled and 1131 were evaluable. For biological-experienced patients (n=1009; analysis population), 82.7% were female, the mean (SD) age was 56.2 (12.4) years, disease duration was 11.8 (9.3) years and the 28-joint Disease Activity Score (erythrocyte sedimentation rate; calculated) was 5.7 (1.2). In total, 407/1009 (40.3%) remained on abatacept at 24 months. Baseline characteristics for patients who completed 2 years of follow-up were similar to the analysis population (see online [supplementary table](http://rmdopen.bmj.com/lookup/suppl/doi:10.1136/rmdopen-2015-000228/-/DC1)).

Concomitant glucocorticoids were used in 734/1009 (72.7%) patients. The proportion of patients with glucocorticoid dose \>5 mg/day decreased over time from 53.8% at abatacept initiation to 29.3% at 24 months ([figure 1](#RMDOPEN2015000228F1){ref-type="fig"}). For patients on abatacept at 24 months with available data (n=216), 8.8% increased and 40.7% decreased the glucocorticoid dose. Specifically, 26.9% decreased their glucocorticoid dose from \>5.0 to ≤5.0 mg/day and 4.6% increased their dose from ≤5.0 to \>5.0 mg/day. Glucocorticoid dose was also assessed using different dose cut-offs, including 7.5 mg/day, with similar findings (see online [supplementary figure](http://rmdopen.bmj.com/lookup/suppl/doi:10.1136/rmdopen-2015-000228/-/DC1)). The 5 mg/day dose data are reported here as it was the most stringent dose cut-off used.
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Median glucocorticoid dose (range) at abatacept initiation was 7.5 (1.0--250.0) mg/day in patients with available data on glucocorticoid dose at initiation (n=692), and 6.0 (2.0--30.0) mg/day in patients with available data at both abatacept initiation and 24 months (n=217) versus 5.0 (0.5--25.0) mg/day (n=232) at 24 months.

Studies that adequately describe concomitant use of glucocorticoids and biological agents are relatively few,[@R7] although some have shown that successful treatment strategies that include biological agents can lead to glucocorticoid dose reduction over time.[@R8] Real-world analyses and registry data show wide variation in glucocorticoid prescribing patterns.[@R11]

Over 24 months after abatacept initiation, 40.7% of patients were able to reduce their glucocorticoid dose; a reduction in median glucocorticoid dose mostly occurred within the first 3 months following abatacept initiation. As the ACTION study focused on abatacept retention, reasons for glucocorticoid dose changes were not collected. Other limitations include the observational design, potential for referral and channelling bias and lack of an active comparator. Nevertheless, this is the first prospective study to analyse concomitant glucocorticoid treatment patterns and doses with abatacept in a real-world setting. The reduction and/or cessation of glucocorticoids was possible in patients with established RA and prior exposure to biological agents who were treated with intravenous abatacept. The clinical importance of these findings is reflected in current EULAR recommendations wherein glucocorticoids can be considered part of the initial 6-month combination treatment with the recommendation to taper as rapidly as clinically feasible.[@R1]
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